Syra HealthSYRA -3.02%12 EBITDA Margin % is 10.73% as of Mar. 2026. GuruFocus rates SYRA with a GF Score™ of 12/100 and a GF Value™ of $0.23 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Syra Health ranks worse than 76.2% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Syra Health's EBITDA for the
three
months ended in Mar. 2026 was $0.24 Mil. Syra Health's Revenue for the
three
months ended in Mar. 2026 was $2.27 Mil. Therefore, Syra Health's EBITDA margin for the quarter that ended in Mar. 2026 was 10.73%.
Syra Health (OTCPK:SYRA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Syra Health EBITDA Margin % Related Terms
Syra Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Syra Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SYRA vs NIVF, BICX, HLYK: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Syra Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syra Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Syra Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Syra Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syra Health (SYRA) has a EBITDA Margin % of 10.73% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syra Health and its competitors. According to the industry distribution chart, Syra Health ranks #506 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 76.2%.
Is Syra Health's EBITDA Margin % too high?
Syra Health's current EBITDA Margin % is 10.73%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Syra Health's value of 10.73% is 5.1% above this industry median. Based on the distribution chart, Syra Health ranks #506 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Syra Health has a GF Score™ of 12/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Syra Health's EBITDA Margin % compare to NIVF and BICX?
According to the Healthcare Providers & Services industry distribution chart, Syra Health ranks #506 out of 664 companies for EBITDA Margin %. This places Syra Health in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Syra Health's value of 10.73% is 5.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syra Health's current EBITDA Margin % of 10.73% is 5.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syra Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syra Health's current EBITDA Margin % is 10.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syra Health stock overvalued right now?
Based on GuruFocus' analysis, Syra Health (SYRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.23, compared to a current price of $0.71 — trading 207.7% above its estimated fair value. The current EBITDA Margin % is 10.73% and 5.1% above the Healthcare Providers & Services industry median of 10.21. Syra Health's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Syra Health (SYRA), the current EBITDA Margin % is 10.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syra Health (SYRA) Overvalued in 2026?
Based on GuruFocus' analysis, Syra Health stock appears to be overvalued.
The current stock price of $0.71 is trading 207.7% above its estimated GF Value™ of $0.23.
GuruFocus considers Syra Health to be Significantly Overvalued.
Key valuation signals for SYRA:
EBITDA Margin %: 10.73%
GF Value™: $0.23 vs. price of $0.71 (207.7% above fair value)
Industry Position: 5.1% above the Healthcare Providers & Services median (#506 of 664)
No single metric tells the full story. See the SYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syra Health Corp is an integrated healthcare solutions company serving government and commercial healthcare organizations. It delivers end-to-end capabilities across population health, behavioral and mental health, digital health, health education and training, and healthcare workforce development and staffing. The various services offered by the company include Syrenity, a mental health application providing preventative care and interventions for behavioral and mental health conditions; SyraBot, a chatbot offering members access to necessary information via the firm's AI-powered customer support chat system; CarePlus, an electronic medical records solution designed for small to mid-sized healthcare organizations; and patient engagement and education services, among others.
12GF Score
Get the complete analysis for SYRA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYRA has been successfully added to your 
